Our Story
At Ravenna Center for Neuropsychiatry, we believe that healing is deeply personal—there is no one-size-fits-all approach. Our mission is simple: to help people find meaningful relief when standard psychiatric treatments have fallen short. We specialize in supporting patients struggling with depression, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and anxiety, particularly those who have not found the relief they need from medications or traditional therapy. Our physician-led approach emphasizes careful evaluation, thoughtful treatment planning, and individualized care.
Founded in 2025 by Dr. Molly Davis, a pioneer in Seattle's interventional psychiatry space, Ravenna Center for Neuropsychiatry was created to redefine what compassionate, patient-centered care can look like. Her vision was to build a clinic that combines evidence-based treatment methods with a unique commitment to understanding each patient on a deeply personal level.​
​
Our clinic is intentionally small, creating a high-touch environment where comfort, privacy, and support are prioritized. Quiet resting rooms and dedicated spaces allow patients to recharge between treatment sessions, ensuring that care is both effective and restorative. We believe in empowering patients with knowledge, fostering safe exploration of new approaches, and supporting informed choices on their healing journey.
​
We understand how challenging life can feel when depression, anxiety, or PTSD are present. Our goal is simple: to help people move toward relief, regain hope, and rediscover a sense of possibility in their lives. At Ravenna Center for Neuropsychiatry, we’re not just treating symptoms—we’re creating the path to lasting wellness.
Meet the Doctor
Molly Davis, MD
Founder & Medical Director
Education
Fellowship:
Geriatric Psychiatry
Oregon Health & Sciences University
​
Residency:
Adult Psychiatry
Oregon Health & Sciences University
Medical School:
University of Washington​
​
Undergraduate:
Stanford University
Board Certifications
Psychiatry
American Board of Psychiatry & Neurology
​
Geriatric Psychiatry
American Board of Psychiatry & Neurology​
Dr. Molly Davis is a dual board-certified general and geriatric psychiatrist with advanced expertise in interventional psychiatry. Over more than 20 years, Dr. Davis has worked in academic and community settings, with a focus on complex neuropsychiatric illness, geriatric psychiatry, and interventional psychiatric care. Earlier in her career, she treated patients extensively with electroconvulsive therapy (ECT) and specialized in neurocognitive and movement disorders.
Since 2011, she has practiced clinical transcranial magnetic stimulation (TMS), transitioning to an exclusive TMS focus by 2014. She has delivered TMS in outpatient settings across conventional once-daily protocols, accelerated protocols, and advanced coil technologies. Her interventional experience also includes reviewing hundreds of cases involving community-based intravenous ketamine treatments and previously offering intranasal esketamine. Her work reflects a systems-level understanding of interventional psychiatry, spanning neuromodulation and emerging psychedelic therapies.
​
Dr. Davis served as site principal investigator on a pivotal clinical trial comparing conventional once-daily TMS with accelerated intermittent theta burst stimulation (multiple daily sessions of TMS, allowing for treatment to be compressed into 5-6 days). She also served as the Seattle site principal investigator for a psychedelic medicine trial investigating a new psychedelic compound to treat postpartum depression. She is trained through MAPS in MDMA-assisted therapy and completed a year-long fellowship in psychedelic medicine through the Integrative Psychiatry Institute.
Her clinical approach is informed by lived experience as a patient, surviving triple-negative breast cancer followed by acute myeloid leukemia. She understands the challenges of navigating the medical system from a patient perspective. She is committed to working with individuals facing life-threatening illness, chronic disease, and existential distress, and to advancing interventional and psychedelic-informed treatments.